Literature DB >> 19506064

Anidulafungin treatment of candidal central nervous system infection in a murine model.

Cheol-In Kang1, Mark S Rouse, Jayawant N Mandrekar, James M Steckelberg, Robin Patel.   

Abstract

We established a murine model of Candida albicans central nervous system (CNS) infection and evaluated the efficacy of anidulafungin. Ten milligrams/kg/day anidulafungin, amphotericin B, or voriconazole significantly reduced mortality and fungal burden in brain tissue, although amphotericin B and 10 mg/kg/day anidulafungin reduced fungal burden in brain tissue to a greater extent than did voriconazole. This suggests a potential role for anidulafungin in the treatment of candidal CNS infection.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19506064      PMCID： PMC2715626          DOI： 10.1128/AAC.00646-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Worst-rank score analysis with informatively missing observations in clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1999-10

Review 2.  The central nervous system and infection by Candida species.

Authors:  J Sánchez-Portocarrero; E Pérez-Cecilia; O Corral; J Romero-Vivas; J J Picazo
Journal:  Diagn Microbiol Infect Dis       Date:  2000-07       Impact factor: 2.803

3.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Development of a plasma high-performance liquid chromatographic assay for LY303366, a lipopeptide antifungal agent, and its application in a dog pharmacokinetic study.

Authors:  L L Zornes; R E Stratford
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-08-01

Review 5.  Anidulafungin: a novel echinocandin.

Authors:  Jose A Vazquez; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2006-06-09       Impact factor: 9.079

6.  Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Lei Ma; Mark R Deziel; Michael F Drusano; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

7.  Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection.

Authors:  Carolina Serena; F Javier Pastor; Marçal Mariné; M Mar Rodríguez; Josep Guarro
Journal:  J Antimicrob Chemother       Date:  2007-05-04       Impact factor: 5.790

8.  Innate immunity to pneumococcal infection of the central nervous system depends on toll-like receptor (TLR) 2 and TLR4.

Authors:  Matthias Klein; Bianca Obermaier; Barbara Angele; Hans-Walter Pfister; Hermann Wagner; Uwe Koedel; Carsten J Kirschning
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

9.  In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

Authors:  D Andes; D J Diekema; M A Pfaller; R A Prince; K Marchillo; J Ashbeck; J Hou
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

10.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245
View more
  2 in total

1.  Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis.

Authors:  Amy M Flattery; Emily Hickey; Charles J Gill; Mary Ann Powles; Andrew S Misura; Andrew M Galgoci; Joan D Ellis; Rena Zhang; Punam Sandhu; John Ronan; George K Abruzzo
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

Review 2.  The use of antifungal therapy in neonatal intensive care.

Authors:  Daniela Testoni; P Brian Smith; Daniel K Benjamin
Journal:  Clin Perinatol       Date:  2012-01-11       Impact factor: 2.642
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.